News

‘Decoy’ Protein Offers New Treatment Approach For Covid-19 – (Forbes.com)

February 3, 2022

Recently William Haseltine wrote an excellent article on Forbes regarding ACE2 research and the development of therapeutics for SARS-Cov2. The article includes a link to research performed by Cyrus scientists Erik Procko …

Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar

January 28, 2022

Date: Thursday, February 3, 2022
Time: 2pm ET / 11am PT
Duration: 1 Hour
Sign up here to go to the webinar Improving the discovery of novel drugs with artificial intelligence Last year, Toronto-based Deep …

Cyrus ACE2.v2.4 candidate’s in vivo activity and prevention of lung damage demonstrated by University of Illinois College of Medicine department of Pharmacology – (Nature.com)

January 26, 2022

https://www.nature.com/articles/s41589-021-00965-6

Cyrus Biotechnology’s COVID therapeutic lead, ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant potentially providing long term protection

December 27, 2021

SEATTLE, WA – (BUSINESS WIRE) – Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary platform for biologics discovery that combines software, AI and large-scale parallel protein screening, today announced that …

Cyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug Discovery Firm – (Businesswire)

December 6, 2021

SEATTLE, WA December 6, 2021 — Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary software platform for biologics discovery, today announced the closing of a $18M Series B financing and …

Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins

September 9, 2021

– First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions- -Preclinical data demonstrate synergistic activity of ImmTOR in combination …